© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
September 24, 2021
The prostate-specific membrane antigen-targeted positron emission tomography imaging technique will be part of the National Comprehensive Cancer Network guidelines beginning in 2022.
September 20, 2021
Apalutamide (Erleada, Johnson & Johnson) demonstrated a strong prostate-specific antigen response and high adherence rates in patients with non-metastatic castration-resistant prostate cancer.
September 16, 2021
Survey participants saw potential for immunotherapy use in earlier stages of several diseases, including melanoma, lung cancer, and bladder or urothelial cancer.
September 13, 2021
New research has found that the relative cardiovascular safety of different types of androgen deprivation therapy (ADT) for prostate cancer remains unresolved after the PRONOUNCE trial was terminated early.
September 09, 2021
Calibrations for the European Randomized Study on Prostate Cancer and Prostate Cancer Prevention Trial predictors can forecast cases across different groups than originally targeted.
Prostate cancers grow slowly and rarely cause any health problems, so without regular screening, it is more difficult to identify any cancer in the prostate.
September 08, 2021
This drug class works by interfering with the ability of cancer cells to repair themselves after experiencing damage to their DNA, but how PARP inhibitors selectively kill cancer cells was previously unknown.
August 30, 2021
Relugolix is an orally administered treatment for prostate cancer that works by blocking the pituitary gland from making luteinizing hormone and follicle-stimulating hormone.
August 25, 2021
Active surveillance, intended to avoid unnecessary treatment and the resulting adverse effects, typically involves regular prostate-specific antigen (PSA) screenings, prostate exams, imaging studies, and repeat biopsies to carefully monitor prostate cancer growth or progression without compromising long-term outcomes.
August 12, 2021
New potential medications may continue to expand the role of targeted agents.